Shareholders Equity (Details Textual) $ / shares in Units, $ in Thousands |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
|
Mar. 25, 2020
Employees
$ / shares
shares
|
Oct. 28, 2019
shares
|
Mar. 31, 2020
USD ($)
$ / shares
shares
|
Dec. 31, 2019
Employees
consultants
$ / shares
shares
|
Nov. 30, 2017
shares
|
May 31, 2017
$ / shares
shares
|
|
| Shareholders Equity (Textual) | ||||||
| Common stock, authorized | 60,000,000 | 60,000,000 | ||||
| Common stock, par value | $ / shares | $ 0.0001 | |||||
| Common stock, issued | 22,925,860 | 22,925,860 | ||||
| Common stock, shares outstanding | 22,920,160 | 22,862,835 | ||||
| Preferred stock, par value | $ / shares | $ 0.0001 | |||||
| Preferred stock, shares authorized | 1,000,000 | |||||
| Grant options | $ / shares | $ 914,741 | |||||
| Equity incentive plan, description | There are 101,041 shares available for issuance under the plan | |||||
| Fair value granted | $ | $ 3,600 | |||||
| Issuance of warrants | 236,552 | |||||
| Warrants, description | a. 177,414 upon the filing of a patent application covering any Discovered Target or a Product b. 118,277 upon achievement of the earlier of the following milestone by the Company: (i) execution of an agreement with a pharmaceutical company with respect to the commercialization of any of the Company’s licensed technology or the Consulting IP or a Product (both defined in the 2017 License Agreement) or (ii) the filing of a patent application covering any Discovered Target (as defined in the 2017 License Agreement) or a Product. c. 59,139 upon completion of a Phase 1 clinical trial in respect of a Product. | |||||
| Public warrants, description | ● in whole and not in part; ● at a price of $0.01 per warrant; ● at any time during the exercise period; ● upon a minimum of 30 days’ prior written notice of redemption; ● if, and only if, the last sale price of the Company’s common stock equals or exceeds $16.00 per share for any 20 trading days within a 30-trading day period ending on the third business day prior to the date on which the Company sends the notice of redemption to the warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. | |||||
| Warrants expire years | 5 years | |||||
| Common Stock | ||||||
| Shareholders Equity (Textual) | ||||||
| Common stock, shares outstanding | 22,920,160 | |||||
| Yeda [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Shares of issued warrants | 7,615 | |||||
| Founder [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Shares of issued warrants | 2,974 | |||||
| License Agreement [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Price Per Share | $ / shares | $ 0.0001 | |||||
| Warrants to purchase Ordinary Shares | 591,382 | |||||
| New Incentive Plan [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Common stock, par value | $ / shares | $ 0.0001 | |||||
| Grant options | $ / shares | $ 1,000 | |||||
| Equity incentive plan, description | The aggregate number of shares of Common Stock that may be delivered pursuant to the 2019 Plan will automatically increase on January 1 of each year, commencing on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to four percent (4%) of the total number of Common Stock outstanding on December 31 of the preceding calendar year. Notwithstanding the foregoing, the Board of Directors may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or that the increase for such year will be a lesser number of Common Stock than provided herein. | |||||
| Stock Options [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Purchase of ordinary shares | 74,581 | |||||
| Grant options | $ / shares | $ 527,716 | |||||
| Grant approved | 814,700 | 704,669 | ||||
| Employees consideration | Employees | 65 | 22 | ||||
| Non-tradable options | 79,630 | |||||
| Consideration consultants | consultants | 2 | |||||
| Exercise price | $ / shares | $ 6.21 | $ 1.34 | ||||
| BiomX Israel [Member] | ||||||
| Shareholders Equity (Textual) | ||||||
| Exchange for common shares | 15,069,058 | |||||
| Shares outstanding, percentage | 65.00% | |||||
| Earnout shares, description | A. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2022 is greater than or equal to $16.50 per share. B. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2024 is greater than or equal to $22.75 per share. C. 2,000,000 additional shares of the Company’s Common Stock if the daily volume weighted average price of the Company’s Common Stock in any 20 trading days within a 30-trading day period prior to January 1, 2026 is greater than or equal to $29.00 per share. | |||||
| Purchase of ordinary shares | 1 | |||||
| Purchase common Stock share | 1 | |||||